Company focused on developing precision α-particle radiopharmaceutical oncology drugs and complementary diagnostic imaging agents that have the potential to optimize patient care
- Company focused on developing precision α-particle radiopharmaceutical oncology drugs and complementary diagnostic imaging agents that have the potential to optimize patient care
- Funds from Series A expected to propel two lead radiopharmaceutical programs, VMT01 and VMT-
